scyx-8k_20180614.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 14, 2018

 

 SCYNEXIS, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Delaware

 

001-36365

 

56-2181648

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

101 Hudson Street

Suite 3610

Jersey City, New Jersey

(Address of principal executive offices, including zip code)

 

(201)-884-5485

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 14, 2018, SCYNEXIS, Inc. (the "Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together with the final tally of the number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes, as to each such matter, including a separate tabulation with respect to each of the seven directors.   A more complete description of each matter is set forth in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2018 (the “Proxy Statement”).

Proposal 1: Election of Directors.

The Company's stockholders elected each of the seven nominees proposed by the Company for election as directors, to serve until the 2019 annual meeting of stockholders, and until their successors are elected and have qualified, or until their earlier death, resignation or removal.  The tabulation of votes on this matter was as follows:

Director Nominee

 

Shares Voted For

 

Shares Withheld

Steven C. Gilman, Ph.D.

 

23,209,108

 

1,780,522

Ann F. Hanham, Ph.D.

 

24,704,916

 

284,714

David Hastings

 

24,700,628

 

289,002

Guy Macdonald

 

24,717,028

 

272,602

Patrick Machado

 

24,665,838

 

323,792

Marion McCourt

 

24,702,428

 

287,202

Marco Taglietti, M.D.

 

24,718,846

 

270,784

There were 15,409,779 broker non-votes for this proposal.

 

 

 

 

 

 


Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.  The tabulation of votes on this matter was as follows:

Shares voted for:

39,394,379

Shares voted against:

881,658

Shares abstaining:

123,372

Broker non-votes:

0

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

SCYNEXIS, Inc.

 

 

By:

 

/s/ Marco Taglietti, M.D.

Name:

 

Marco Taglietti, M.D.

Title:

 

Chief Executive Officer

Dated: June 20, 2018